$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

$zvsa Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010259 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.540M	$3.500M
YoY Change	53.91%	207.02%
% of Gross Profit
Research & Development	$1.056M	$399.9K
YoY Change	-1.31%	-36.52%
% of Gross Profit
Depreciation & Amortization	$2.600K	$532.00
YoY Change
% of Gross Profit
Operating Expenses	$4.592M	$820.1K
YoY Change	473.26%	251.66%
Operating Profit	-$4.592M	-$820.1K
YoY Change
Interest Expense	$0.00	-$240.0K
YoY Change	-100.0%	4319.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$4.590M	-$5.420M
YoY Change	537.49%	1599.06%
Income Tax	-$1.047M	-$745.1K
% Of Pretax Income
Net Earnings	-$3.500M	-$75.02K
YoY Change	386.11%	-76.48%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.39	-$0.01
Diluted Earnings Per Share	-$0.39	-$0.51
COMMON SHARES
Basic Shares Outstanding	9.212M shares	9.016M shares
Diluted Shares Outstanding	26.08K shares	257.6K shares

Balance Sheet

Concept	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.300M	$5.900M
YoY Change	56.59%	535.78%
Cash & Equivalents	$1.278M	$5.902M
Short-Term Investments
Other Short-Term Assets	$1.500M	$400.0K
YoY Change	566.67%	58.73%
Inventory
Prepaid Expenses	$1.322M	$225.3K
Receivables
Other Receivables
Total Short-Term Assets	$2.835M	$6.363M
YoY Change	168.63%	439.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.73K	$17.33K
YoY Change
Goodwill	$11.90M	$11.90M
YoY Change
Intangibles		$100.1M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.1M	$100.1M
YoY Change	59735.19%	31.76%
Total Long-Term Assets	$112.1M	$112.1M
YoY Change	42.61%	47.63%
TOTAL ASSETS
Total Short-Term Assets	$2.835M	$6.363M
Total Long-Term Assets	$112.1M	$112.1M
Total Assets	$115.0M	$118.5M
YoY Change	44.28%	53.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.381M	$6.026M
YoY Change	99.41%
Accrued Expenses	$2.113M	$2.054M
YoY Change	155.03%	925.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.578M	$8.188M
YoY Change	935.46%	2857.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.578M	$8.188M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$17.86M	$18.51M
YoY Change	324.78%	406.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.500M	-$4.921M
YoY Change		117.87%
Common Stock	$922.00	$902.00
YoY Change		2718.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$97.10M	$99.66M
YoY Change
Total Liabilities & Shareholders Equity	$115.0M	$118.5M
YoY Change	44.28%	53.62%

Cashflow Statement

Concept	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.500M	-$75.02K
YoY Change	386.11%	-76.48%
Depreciation, Depletion And Amortization	$2.600K	$532.00
YoY Change
Cash From Operating Activities	-$4.600M	-$3.394M
YoY Change	4585.75%	493.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$34.67K
YoY Change	-101.29%
NET CHANGE
Cash From Operating Activities	-$4.600M	-$3.394M
Cash From Investing Activities
Cash From Financing Activities	-$34.67K
Net Change In Cash	-$4.624M	-$3.394M
YoY Change	4610.32%	-719.32%
FREE CASH FLOW
Cash From Operating Activities	-$4.600M	-$3.394M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001859007
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	ZVSA	Vendor Deposit Noncurrent VendorDepositNoncurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q4	ZVSA	Convertible Notes Payable Related Parties Current Portion ConvertibleNotesPayableRelatedPartiesCurrentPortion		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	ZVSA	Interest Expenses InterestExpenses		usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q4	ZVSA	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPppLoan		usd
CY2022Q4	ZVSA	Deemed Dividend To Preferred Stockholders DeemedDividendToPreferredStockholders		usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022Q4	ZVSA	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPppLoan		usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q4	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits		usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts		usd
CY2022Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q4	ZVSA	Gain On Forgiveness Of Paycheck Protection Program Loan GainOnForgivenessOfPaycheckProtectionProgramLoan		usd
CY2022Q4	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Preferred Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoPreferredStock		usd
CY2022Q4	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoCommonStock		usd
CY2022Q4	ZVSA	Recognition Of Rou Asset And Lease Liability Upon Adoption Of Asc842 RecognitionOfRouAssetAndLeaseLiabilityUponAdoptionOfAsc842		usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent		usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent		usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41184
CY2022	dei	Entity Registrant Name EntityRegistrantName	ZYVERSA THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2685744
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2200 N. Commerce Parkway
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 208
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Weston
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33326
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33326
CY2022	dei	City Area Code CityAreaCode	(754)
CY2022	dei	Local Phone Number LocalPhoneNumber	231-1688
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	ZVSA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118506271	usd
CY2022Q2	dei	Entity Public Float EntityPublicFloat	77127889	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9211922	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Orlando, Florida
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2021	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q4	us-gaap	Cash Cash	5902199	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	225347	usd
CY2022Q4	ZVSA	Vendor Deposit VendorDeposit	235000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6362546	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17333	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100086329	usd
CY2022Q4	us-gaap	Goodwill Goodwill	11895033	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	46659	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	98371	usd
CY2022Q4	us-gaap	Assets Assets	118506271	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6025645	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2053559	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108756	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	39942	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8187960	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10323983	usd
CY2022Q4	us-gaap	Liabilities Liabilities	18511943	usd
CY2022	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	65783	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	331331	usd
CY2021	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9016139	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9016139	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	902	usd
CY2021	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104583271	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4921178	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	399894	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	420174	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	820068	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-820068	usd
CY2022Q4	ZVSA	Pretax Net Loss PretaxNetLoss	-820068	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-745050	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-75018	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75018	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9016139	shares
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99681682	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56333	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-75018	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-75018	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	56333	usd
CY2022Q4	us-gaap	Depreciation Depreciation	532	usd
CY2022Q4	us-gaap	Other Noncash Expense OtherNoncashExpense	4443	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-745050	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-36606	usd
CY2022Q4	ZVSA	Increase Decrease In Vendor Deposits IncreaseDecreaseInVendorDeposits	125645	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2076863	usd
CY2022Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4786	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-715730	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3393888	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3393888	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9296087	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5902199	usd
CY2022Q4	ZVSA	Accounts Payable For Deferred Offering Costs AccountsPayableForDeferredOfferingCosts	240691	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zKCaMnshODP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52000	usd
CY2022	ZVSA	Accumulated Depreciation AccumulatedDepreciation	34667	usd
CY2021	ZVSA	Accumulated Depreciation AccumulatedDepreciation	24267	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Depreciation Depreciation	532	usd
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	us-gaap	Depreciation Depreciation	9869	usd
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.58835
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	186401	usd
CY2022	ZVSA	Entity Valution Amount EntityValutionAmount	85000000	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11991694	shares
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.25
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zkKH56g4HY9d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Reclassifications</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.</span></p>
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	6719730	shares
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	5.037	pure
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	699324	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets	1093223	usd
CY2022Q4	ZVSA	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inprocess Research And Development BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInprocessResearchAndDevelopment	100086329	usd
CY2022Q4	us-gaap	Goodwill Goodwill	11895033	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	64523	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	113139108	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	10818204	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	11069033	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	21887237	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	91251871	usd
CY2022Q4	ZVSA	Milestone Payment Liability MilestonePaymentLiability	1500000	usd
CY2021Q4	ZVSA	Milestone Payment Liability MilestonePaymentLiability	1500000	usd
CY2022Q4	ZVSA	Note Payable NotePayable	-351579	usd
CY2021Q4	ZVSA	Note Payable NotePayable	-351579	usd
CY2022Q4	ZVSA	Note Net NoteNet	1148421	usd
CY2021Q4	ZVSA	Note Net NoteNet	1148421	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	584226	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	214229	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	106683	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	748767	usd
CY2021Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	16913	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2053559	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1914101	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3961000	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	709608	usd
CY2022Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	583831	shares
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The automatic conversion was pursuant to the share-settled redemption feature included in the original terms of the Notes which resulted in a conversion price of $1.58835 (80% of the $1.98542 fair value per share of the Predecessor common stock which was determined using the Business Combination exchange ratio of 5.037).
CY2022Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.58835
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2940537	shares
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	788700	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	228100	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	560600	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	607001	usd
	ZVSA	Derivative Liabilities Reclassify To Equity Upon Converstion DerivativeLiabilitiesReclassifyToEquityUponConverstion	1167601	usd
CY2021Q4	ZVSA	Percentage Of Qualified Offering Occurring PercentageOfQualifiedOfferingOccurring	0.85	pure
CY2021Q4	ZVSA	Percentage Of Change Of Control Occuring PercentageOfChangeOfControlOccuring	0	pure
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-151625	usd
CY2022Q4	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-34844	usd
CY2022Q4	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-186469	usd
CY2022Q4	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	558581	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-745050	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036	pure
CY2022Q4	ZVSA	Effective Income Tax Rate Reconciliation Permanent Difference Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent	-0.019	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.000	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.681	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.908	pure
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2021	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6671907	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2936945	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2421390	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Startup Costs DeferredTaxAssetsCapitalizedStartupCosts	1121802	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Licensing Costs DeferredTaxAssetsCapitalizedLicensingCosts	687926	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Patents DeferredTaxAssetsCapitalizedPatents	288123	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	133203	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	71830	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	2833	usd
CY2022Q4	ZVSA	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	26794	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14362753	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14362753	usd
CY2022Q4	ZVSA	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset	24236	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	24658231	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4270	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	24686737	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10323984	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	27515427	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	20567703	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	558581	usd
CY2015Q4	ZVSA	License Agreements Up Front Cash Payment LicenseAgreementsUpFrontCashPayment	200000	usd
CY2015Q4	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	21500000	usd
CY2020Q4	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	1500000	usd
CY2021Q4	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	500000	usd
CY2015Q4	ZVSA	Second License Agreement Milestone Value SecondLicenseAgreementMilestoneValue	2500000	usd
CY2015Q4	ZVSA	Fair Value Of Grant Date Excerisable FairValueOfGrantDateExcerisable	766384	usd
CY2020Q1	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	1000000	usd
CY2020Q1	ZVSA	License Agreements Payable Upon Commencement LicenseAgreementsPayableUponCommencement	500000	usd
CY2020Q1	ZVSA	License Agreements Payable LicenseAgreementsPayable	500000	usd
CY2020Q1	ZVSA	Cash Payment Exercise Price Withheld CashPaymentExercisePriceWithheld	351579	usd
CY2019Q2	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	22500000	usd
CY2019Q2	us-gaap	Description Of Postretirement Medical Plans With Prescription Drug Benefits DescriptionOfPostretirementMedicalPlansWithPrescriptionDrugBenefits	the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%.
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7795	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4786	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y29D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y29D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M18D
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1993235	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1639566	shares
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	112916	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4160	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	108756	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	331331	shares
CY2022Q4	us-gaap	Share Price SharePrice	5.04
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	ZVSA	Satisfaction Of Liabiilites SatisfactionOfLiabiilites	5062000	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	56333	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3524802	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2957047	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y7M6D
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4245463	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2021	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1993235	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.81
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1993235	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.81
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1639566	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.63
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	5.037	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	The Replacement Warrants include (a) exercisable warrants to purchase 1,271,904 shares of Successor common stock with an exercise price of $6.90 per share and with an expiration date of December 12, 2027, which replace the warrants that were issued by the Predecessor to its Series A Preferred Stock holders upon the automatic conversion of their Predecessor Series A Preferred Stock into Predecessor common stock and Predecessor Series A Warrants upon the closing of the Business Combination (see Note 11 – Stockholders’ Permanent and Temporary Equity – Automatic Conversion of Predecessor Series A Preferred Stock); (b) warrants to purchase 104,704 shares of Successor common stock with an exercise price of $5.03 per share which replace the warrants that were issued by the Predecessor to a strategic partner (see Note 10 – Commitments and Contingencies – License Agreements – L&F Research LLC), of which warrants to purchase 34,901 shares are exercisable until they expire on or about January 6, 2025, while the remainder vest upon the achievement of certain milestones and expire five years following the achievement of those milestones; and (c) exercisable warrants to purchase 323,026 shares of Successor common stock with an exercise price of $11.58 per share and with various expiration dates through April 17, 2024 which replace the warrants that were issued by the Predecessor to certain purchasers of convertible notes, certain brokers and a strategic partner in conjunction with entering into a license agreement (see Note 10 – Commitments and Contingencies – License Agreements – InflamaCORE).
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor

Files In Submission

Name	View Source	Status
zvsa-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
zvsa-20221231_cal.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
0001493152-23-010259-index-headers.html	Edgar Link	pending
0001493152-23-010259-index.html	Edgar Link	pending
0001493152-23-010259.txt	Edgar Link	pending
0001493152-23-010259-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-8.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
form10-k_011.jpg	Edgar Link	pending
form10-k_012.jpg	Edgar Link	pending
form10-k_013.jpg	Edgar Link	pending
form10-k_014.jpg	Edgar Link	pending
form10-k_015.jpg	Edgar Link	pending
form10-k_016.jpg	Edgar Link	pending
form10-k_017.jpg	Edgar Link	pending
form10-k_018.jpg	Edgar Link	pending
form10-k_019.jpg	Edgar Link	pending
form10-k_020.jpg	Edgar Link	pending
form10-k_021.jpg	Edgar Link	pending
form10-k_022.jpg	Edgar Link	pending
form10-k_023.jpg	Edgar Link	pending
form10-k_024.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zvsa-20221231.xsd	Edgar Link	pending
zvsa-20221231_def.xml	Edgar Link	unprocessable
zvsa-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

2023 Q1 Form 10-K Financial Statement

#000149315223010259 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA ZyVersa Therapeutics, Inc. Stock $zvsa

2023 Q1 Form 10-K Financial Statement

#000149315223010259 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa